Each ml ophthalmic solution contains Bromfenac 0.9mg as Bromfenac sodium INN.
Bromfenac ophthalmic solution is indicated for treatment of postoperative inflammation and in patients who have undergone cataract extraction, prevention of miosis in cataract surgery, treatment of pseudophakic cystoid macular edema (CME), treatment of external anterior ocular inflammatory diseases such as blepharitis, conjunctivitis and scleritis.
Each ml ophthalmic solution contains Bromfenac 0.9mg as Bromfenac sodium INN.
Bromfenac ophthalmic solution is indicated for treatment of postoperative inflammation and in patients who have undergone cataract extraction, prevention of miosis in cataract surgery, treatment of pseudophakic cystoid macular edema (CME), treatment of external anterior ocular inflammatory diseases such as blepharitis, conjunctivitis and scleritis.
Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.